Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 537 shares at $26.18 ($14K) on 2024-09-10, disclosed to the SEC on 2024-09-13.
Open-market sale of $14k AKRO by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |